Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms

This study aims to retrospectively evaluate the efficacy and safety of the Surpass Evolve Flow Diverter in treating complex intracranial aneurysms. It seeks to assess long-term outcomes and complication rates while analyzing the impact of patient characteristics and aneurysm types on treatment effectiveness. By collecting data from multiple centers, the study ensures broad representativeness, ultimately providing valuable insights for clinical management on a global scale.

Inclusion Criteria:

1. Age ≥ 18 years with a confirmed diagnosis of intracranial aneurysm.
2. Imaging studies confirming suitability for Surpass Evolve Flow Diverter treatment.
3. Aneurysms meeting flow diverter treatment indications (e.g., aneurysms larger than 4 mm).
4. At least six months of follow-up data available post-treatment.

Exclusion Criteria:

1. Patients with acutely ruptured aneurysms or significant bleeding.
2. Patients with incomplete data or insufficient follow-up records.

Chinese populations with intracranial aneurysms